Invex Therapeutics Cash Flow Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019
Period Ending	Dec '24 Dec 31, 2024	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020	2019
Net Income	0.11	-1.64	-7.75	-3.95	-2.28	-3.36	Upgrade
Asset Writedown & Restructuring Costs	-	-	-	-	-	0.12	Upgrade
Stock-Based Compensation	0.14	0.14	0.48	0.35	0.56	0.98	Upgrade
Other Operating Activities	0.28	-0.04	0.02	0	0	-0.01	Upgrade
Change in Accounts Receivable	0.24	0.24	-0.19	-0.12	0.1	0.04	Upgrade
Change in Accounts Payable	-1.14	-1.14	0.57	0.35	-0.05	0.62	Upgrade
Operating Cash Flow	-0.37	-2.44	-6.87	-3.38	-1.68	-1.6	Upgrade
Issuance of Common Stock	-	-	-	-	8.65	17.55	Upgrade
Repurchase of Common Stock	-	-14	-	-	-	-	Upgrade
Other Financing Activities	-	-	-	-	-0.55	-1.82	Upgrade
Financing Cash Flow	-	-14	-	-	8.09	15.73	Upgrade
Net Cash Flow	-0.35	-16.45	-6.87	-3.38	6.42	14.13	Upgrade
Cash Income Tax Paid	-	-1.21	-0.46	-	-	-	Upgrade
Levered Free Cash Flow	-0.47	-2.1	-4.48	-1.95	-2.23	0	Upgrade
Unlevered Free Cash Flow	-0.47	-2.1	-4.48	-1.95	-2.23	0	Upgrade
Change in Net Working Capital	0.43	0.9	-0.38	-0.22	1.26	-1.05	Upgrade

Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.